Results 171 to 180 of about 6,459 (257)

Supporting Weight Management for Kidney Transplant Candidates in People With Obesity on Haemodialysis: The First National Survey of UK Kidney Healthcare Providers

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7116-7125, August 2026.
ABSTRACT Aims Access to kidney transplantation (KTx) for people living with obesity and kidney failure is often challenging, especially given the inconsistent availability of publicly funded obesity services across the United Kingdom. This study explored UK kidney healthcare providers' views on weight management support for patients with obesity on ...
Adrian Brown, Helen L. MacLaughlin, Kieran McCafferty, Sebastian Potthoff, Sharlene Greenwood, Victoria Vickerstaff, Rachel L. Batterham, Rachel Thomas, Claudia Hobbs, Reza Motallebzadeh   +9 more
wiley   +1 more source

GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives. [PDF]

Front Med (Lausanne)
Fang Q, Zhu Y, Rao M, Liu P.
europepmc   +1 more source

Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7126-7136, August 2026.
ABSTRACT Aims To compare sleeve gastrectomy (SG) with intensive lifestyle modification combined with obesity management medications (ILM/OMMs) in adults with severe obesity, focusing on BMI trajectory, time to achieving clinically meaningful weight loss, and metabolic outcomes in a real‐world clinical setting.
Maria Francesca Russo, Giovanni Casella, Giulia Angelini, Sara Russo, James Casella‐Mariolo, Vito D'Andrea, Giulio Illuminati, Lidia Castagneto‐Gissey   +7 more
wiley   +1 more source

Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials. [PDF]

Front Med (Lausanne)
Harbi MH, Ashour AM, Alorfi NM, Aldurdunji MM, Wali SM, Alzahrani YA.   +5 more
europepmc   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6533-6549, August 2026.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations. [PDF]

Diabetes Care
Ostrominski JW, Ortega-Montiel J, Wexler DJ, Everett BM, Cromer SJ, Byrne CF, Glynn RJ, Paik JM, Patorno E.   +8 more
europepmc   +1 more source

Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6985-6996, August 2026.
ABSTRACT Aim To evaluate the 12‐month effectiveness and patient persistence of a semaglutide‐supported digital weight‐loss service (DWLS) in a real‐world German cohort. Methods This retrospective study analysed 4535 patients who initiated the Juniper Germany DWLS. Primary endpoints included 12‐month medication and data submission adherence (receiving ≥ 
Louis Talay, Jason Hom, Marilyn Tan, Neera Ahuja   +3 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes. [PDF]

Diabetes Ther
Panou T, Gouveri E, Popovic DS, Papazoglou D, Papanas N.   +4 more
europepmc   +1 more source

Risk of Psychiatric Worsening With GLP‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7048-7057, August 2026.
ABSTRACT Aims To compare 1‐year psychiatric outcomes after GLP‐1 receptor agonist (GLP‐1 RA) versus sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) initiation in patients with type 2 diabetes and treated depression. Materials and Methods We conducted a retrospective active‐comparator, new‐user cohort study using electronic health records from the ...
Yu Chang, Ming‐Hong Hsieh, Po‐Chung Ju, Cheng‐Chen Chang   +3 more
wiley   +1 more source

Tirzepatide improved markers of islet cell function and insulin sensitivity in people With T2D (SURPASS-2)

: Context In previous SURPASS studies tirzepatide reduced hemoglobin glycated A1c (HbA1c) and body weight and improved markers of insulin sensitivity and beta-cell function to a greater extent than comparators.
Frias, Juan P., Wang, Hui, de Block, Christophe, Zeytinoglu, Meltem, Maldonado, Juan M., Thomas, Melissa K., Brown, Katelyn   +6 more
core